FIELD GUIDE · AI, MEDICINE & THE MOLECULE RACE
AI can reject a bad drug on a screen before anyone wastes weeks brewing it in a lab. The question is whether faster candidates become better medicines.
UPDATED 2026-10-12
TL;DR
01
McKinsey reported that selected publicly disclosed AI-enabled programs with enough available data reached first-in-human or comparable preclinical milestones 15 to 80 percent faster than large-pharma medians, depending on target novelty and modality. Real compression — from a selected, self-reported set. Not the whole industry.
02
McKinsey rates molecule design as the most mature part of the chain because chemical data and assay feedback are comparatively structured and fast. It rates target identification lower and preclinical translation lower still. AI dominates where the answer can be scored quickly. The hardest failures happen where feedback is slow and messy.
03
Nature Medicine reported a randomized Phase 2a trial of rentosertib, whose TNIK target and small molecule were developed with generative-AI tools. The study found comparable overall adverse-event rates across groups and a lung-function signal at the highest dose, while concluding that larger and longer trials were needed. Past the molecule-demo stage. One encouraging trial does not prove the industry-wide win rate.
04
A 2026 Nature Reviews Drug Discovery perspective concluded that evidence of clinically relevant impact from AI in drug discovery remains limited and argued that evaluation must move beyond model benchmarks toward whether AI improves real project decisions. Better evidence that AI accelerates parts of discovery than that it reliably produces safer or more effective approved drugs.
KEEP READING
NEXT FIELD GUIDE →SHOULD A ROBOT DECIDE YOUR DIAGNOSIS?AI already writes the notes, summarizes the research, and flags the scans. The fight starts when its suggestion becomes your treatment plan.A billionaire who builds surveillance software fears a world government promising protection. Douthat pressed him in 2025. Then came the secret lectures, the pope, the AI safetyists — and an Iran-war break with Trump.
Peter Thiel made his fortune on the internet and keeps insisting the internet was not enough. Flying cars, Mars, AI, longevity and the meaning of progress — the other half of his worldview.
Washington is trying to choke off China's AI — chip bans, blacklists, and now Taiwan making smuggling a crime. Beijing just returned the favor, locking down its own AI exports. Meanwhile the models keep getting cheaper, better, and closer together. A field guide to the argument over whether the race protects anyone, or just speeds everything up.
SHOW YOUR WORK
The early cycle is moving. The approval rate is still the proof.